Skip Nav Destination
Issues
1 July 2012
-
Cover Image
Cover Image
![issue cover]()
Deregulation of TGF-β superfamily signaling is a causative factor in many diseases. Bivalent single-chain traps that neutralize TGF-β family ligands (green and orange) were rationally designed using native intrinsically disordered regions as linkers (black) between two cognate receptor binding domains (magenta). TGF-β traps designed by this innovative strategy can achieve similar or better in vitro potency and in vivo tumor growth inhibition compared to a neutralizing antibody, indicating their promising therapeutic potential. For details, see article by Zwaagstra and colleagues on page 1477.Close Modal - PDF Icon PDF LinkTable of Contents
ISSN 1535-7163
EISSN 1538-8514
Highlights
Spotlight on Clinical Response
Therapeutic Discovery
Adenosine A2A and Beta-2 Adrenergic Receptor Agonists: Novel Selective and Synergistic Multiple Myeloma Targets Discovered through Systematic Combination Screening
Richard J. Rickles; Winnie F. Tam; Thomas P. Giordano, III; Laura T. Pierce; Melissa Farwell; Douglas W. McMillin; Antoaneta Necheva; David Crowe; Mei Chen; William Avery; Vikram Kansra; Steffan T. Nawrocki; Jennifer S. Carew; Francis J. Giles; Constantine S. Mitsiades; Alexis A. Borisy; Kenneth C. Anderson; Margaret S. Lee
Inhibition of ATR-Dependent Signaling by Protoapigenone and Its Derivative Sensitizes Cancer Cells to Interstrand Cross-link–Generating Agents In Vitro and In Vivo
Hui-Chun Wang; Alan Yueh-Luen Lee; Wen-Cheng Chou; Chin-Chung Wu; Chao-Neng Tseng; Kevin Yen-Ting Liu; Wen-Lien Lin; Fang-Rong Chang; Da-Wei Chuang; Attila Hunyadi; Yang-Chang Wu
Engineering and Therapeutic Application of Single-Chain Bivalent TGF-β Family Traps
John C. Zwaagstra; Traian Sulea; Jason Baardsnes; Anne E.G. Lenferink; Cathy Collins; Christiane Cantin; Béatrice Paul-Roc; Suzanne Grothe; Sazzad Hossain; Louis-Philippe Richer; Denis L'Abbé; Roseanne Tom; Brian Cass; Yves Durocher; Maureen D. O'Connor-McCourt
Preclinical Development
Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells
C. Elizabeth Caldon; C. Marcelo Sergio; Jian Kang; Anita Muthukaruppan; Marijke N. Boersma; Andrew Stone; Jane Barraclough; Christine S. Lee; Michael A. Black; Lance D. Miller; Julia M. Gee; Rob I. Nicholson; Robert L. Sutherland; Cristin G. Print; Elizabeth A. Musgrove
Characterization of an Oxaliplatin Sensitivity Predictor in a Preclinical Murine Model of Colorectal Cancer
Mickey K. Kim; Takuya Osada; William T. Barry; Xiao Yi Yang; Jennifer A. Freedman; Katherine A. Tsamis; Michael Datto; Bryan M. Clary; Timothy Clay; Michael A. Morse; Philip G. Febbo; H. Kim Lyerly; David S. Hsu
Effect of a Low-Fat Diet Combined with IGF-1 Receptor Blockade on 22Rv1 Prostate Cancer Xenografts
Ramdev Konijeti; Satomi Koyama; Ashley Gray; R. James Barnard; Jonathan W. Said; Brandon Castor; David Elashoff; Junxiang Wan; Pedro J. Beltran; Frank J. Calzone; Pinchas Cohen; Colette Galet; William J. Aronson
Preclinical Analysis of the γ-Secretase Inhibitor PF-03084014 in Combination with Glucocorticoids in T-cell Acute Lymphoblastic Leukemia
Jeremy B. Samon; Mireia Castillo-Martin; Michael Hadler; Alberto Ambesi-Impiobato; Elisabeth Paietta; Janis Racevskis; Peter H. Wiernik; Jacob M. Rowe; John Jakubczak; Sophia Randolph; Carlos Cordon-Cardo; Adolfo A. Ferrando
Molecular Medicine in Practice
The Association of PI3 Kinase Signaling and Chemoresistance in Advanced Ovarian Cancer
Craig P. Carden; Adam Stewart; Parames Thavasu; Emma Kipps; Lorna Pope; Mateus Crespo; Susana Miranda; Gerhardt Attard; Michelle D. Garrett; Paul A. Clarke; Paul Workman; Johann S. de Bono; Martin Gore; Stan B Kaye; Udai Banerji
Advertisement
